Atıf İçin Kopyala
Ak N., Vatansever S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.46, sa.6, ss.1787-1791, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
46
Sayı:
6
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1111/jcpt.13364
-
Dergi Adı:
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
-
Sayfa Sayıları:
ss.1787-1791
-
Anahtar Kelimeler:
atezolizumab, immunotherapy, microsatellite instability, ovarian cancer, PD-L1
-
İstanbul Üniversitesi Adresli:
Evet
Özet
What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.